Home
overview

Sample quality and validity are key factors in biobanking. Organisations are looking to reduce R&D spending and they are looking at samples, human tissue, for example as they are more reliable in clinical settings. SMi's 4th annual event in 2014 will follow on from the highly successful one in 2013.

We are very excited to present the 4th annual conference on Biobanking. This event is well established and is highly regarded in the biobanking field. The focus of this year's event will be on how biobanking can move forward in terms of strategy, regulation, ethics and sample quality. The conference will evaluate the challenges that many pharmaceutical companies are facing in terms of sample access and sample quality; the event will also examine the importance of networking and partnerships within biobanking.

This event will bring together industry leaders from big pharma companies, biotech companies, regulatory agencies and academia to discuss the latest developments in biobanking. This unique conference will present attendees with a complete view into the latest research and work being done in biobanking. The conference will comprise a number of presentations and case studies from key opinion leaders and updates on their latest projects, successes and challenges.

2013 testimonials:

‘Excellent. A wide variety of speakers!’ Research Associate, University of Cambridge
‘Topics were interesting and informative’ Novartis
‘Pertinent and interesting presentations, very useful’ NHS
 

• More emphasis on how companies are using their samples
• How will the data handling directive affect the biobanking industry?
• Diversity of speakers discussing challenges and biobanking case studies
• Discuss the importance of networking within biobanking
• Developing an effective strategy within biobanking
 

Heads of Department, Directors, Managers, Team Leaders of:
Biobanking
Biorepository
Biological Sample Management
Biosample Management
Pharmacogenomics
Pathology
Genomics
Personalised Medicine
Translational Medicine
Lab Management
Inventory Management
Molecular Technologies
Biologics Research
Data Privacy/Protection/Security Officers
Quality Control and Quality ManagementResearch and Development
Supply Chain
Population based biobanks
Disease based biobanks
Hospital Trusts
Research Institutes
Tecnology Transfer
Bioinnovation


 

 

June 2013 attendees included:

Areteva; AstraZeneca; Bayer Pharma AG; BBI Solutions; Cambridge University; Chernobyl Tissue Bank; Covington & Burling Llp; Daiichi Sankyo Europe GmbH; Elpro UK Ltd; Elpro-Buchs AG; Faculty of Military Health Sciences; FLUIDX; GlaxoSmithKline; Human Tissue Authority; Hunt Biosciences; Independent Consultancy ; Institute Of Neurology; King’s College London; Kings College London; McGill University Department of Human Genetics; Medical Research Council; Meso Scale Discovery; Meso-Scale; National Institute For Biological Standards & Control; Newcastle University Business School; NIBSC; Nottingham University Hospitals NHS Trust; Novartis; Novartis Horsham Research Centre; Novartis Pharma AG; Pirkanmaa Hospital District; Stoke Mandeville Hospital N H S Trust; Tissue Solutions; UCL Medical School Royal Free Campus; UCLH BioResources; University College London; University Of Bari; University Of Bergen; University of Buenos Aires; University of Manchester; University of Nottingham; University Of Southampton; University of Texas, Anderson Cancer Center; Weil Cornell Medical College;

Conference programme

8:30 Registration and coffee

9:00 Chairman's opening remarks

Brian Thomson

Brian Thomson, Director, Nottingham Health Science Biobank

9:10 Maximising the value of biosamples

Brian Thomson

Brian Thomson, Director, Nottingham Health Science Biobank

  • Measuring the value of the biosamples
  • Ensuring sustainability of sample collection
  • Adding value to the biosample: clinical and pathological annotation
  • Biosamples as part of the electronic health record
     
     
  • 9:50 Case study: Establishing a repository for patient samples from clinical studies

    Mads Roepke

    Mads Roepke, Senior Scientific Advisor, Leo Pharma

     

  • Creating biobanking structures to enable future research on clinical patient samples
  • Implementing framework for combining molecular profiling of samples with patient metadata
  • Evaluating practical, legal and regulatory implications
  • An industry perspective
     
  • 10:30 Morning coffee

    11:00 Maintaining sample quality for future research

    Berthold Huppertz

    Berthold Huppertz, Director and CEO of Biobank Graz , University Hospital

  • Exploring technology as an advantage
  • Mitigating the risks of bad storage of samples
  • Emerging issues in sample quality strategically
  • Harmonization of sample quality in biobank networks
  • 11:40 The Next Generation Biobank: Liberate the knowledge from your biospecimens to enable precision medicine

    Mark Collins

    Mark Collins, Director of Marketing, BioFortis, Inc.

     

    •  Maximizing the value of your specimens through harmonization of data
    •  Enhancing security and compliance
    • Tracking consent
    • Generating scientific insights to enable future biomedical research
       

       

    12:20 Challenges in reusing samples: developing an effective consent form

    Anne Bahr

    Anne Bahr, Data Protection Officer, Sanofi-Aventis

  • Introduction to EU Personal Data Protection principles and their application to Human Biological Samples
  • Coding, withdrawl and re-using of personal data and biological samples
  • What should be included in the Informed Consent form?
  • Last updates regarding the new EU Data Protection regulation draft
  • 13:00 Networking lunch

    14:00 The importance, practicalities and challenges of brain banking

    Claire Troakes

    Claire Troakes, Brain Bank Coordinator, London Neurodegenerative Diseases Brain Bank, Kings College London

  • CNS tissue banking in the UK
  • The importance of tissue banking in CNS research
  • Challenges associated with Brain Banking
  • Looking to the future
  • 14:40 The AstraZeneca Biobank Application (ABBA)

    Steve Kelly

    Steve Kelly, Team Leader, R&D, Astra Zeneca

     

     

     

  • Highly detailed level of sample tracking
  • Standardised sample characterisation data across clinical studies
  • Improved visibility of sample catalogue
  • Improved governance over samples
     
  • 15:20 Supporting Biobanks and bioResources at UCL

    Dr Kirstin Goldring

    Dr Kirstin Goldring, UCL Biobank and BioResource Coordinator, University College London

     

  • Diversity of biobanking requirements in academia
  • A biobanking model to support academics
  • Tissue access for patient benefit
  • A national approach to BioResources
  • 16:00 Chairman's closing remarks

    16:10 Afternoon tea

    8:30 Registration and coffee

    9:00 Chairman's opening remarks

    Brian Thomson

    Brian Thomson, Director, Nottingham Health Science Biobank

    9:10 Impact of the new Data protection regulation on biobanking

    Emmanuelle Rial-Sebbag

    Emmanuelle Rial-Sebbag, Permanent Research Fellow, INSERM

  • Assessing the forthcoming regulation in the context of biobanks
  • Participants protection in research biobanking, new rights from the data protection regulation
  • Impact of the forthcoming regulation on research biobanking in the light of European infrastructures 
  •  Impact of the forthcoming regulation on the industry and academia partnerships
  • 9:50 Ethics in biobanking - a CoE perspective

    Javier Arias Diaz

    Javier Arias Diaz, Co-ordinator of the Council of Europe Bioethics Committee on Biobanks, Council Of Europe

  • ·          Ethical principles at stake
  • ·          The dilemma of informed consent
  • ·          The importance of a good policy
  • ·          Building trust
  • 10:30 Morning coffee

    11:00 Moving from clinical sample to laboratory measurement: automating epidemiological research

    Matt Sims

    Matt Sims, Head of Research Operations , MRC Epidemiology Unit, University of Cambridge School of Clinical Medicine

     

     
  • Highlight the challenges associated with accessing and measuring clinical samples for large scale epidemiology research
  • Use of automation for efficiently accessing and preparing samples for measurement
  • Case studies for projects producing genetic and clinical biochemistry research measurements from thousands of samples
  • Methods for controlling measurement error and maximising research application
  • 11:40 The UK ME/CFS Biobank experience

    Caroline Kingdon

    Caroline Kingdon, Research Nurse, London School of Hygiene & Tropical Medicine

  • Patient oriented resource building
  • Infrastructure for data and sample gathering
  • Open access for academics and industry
  • Sustainability of a disease specific biobank
  • 12:20 Networking lunch

    13:40 'Breaking through informatics complexity

    Neil Benn

    Neil Benn, Managing Director, Ziath Ltd

  • ·          Large-scale randomised and observational evidence is needed to investigate reliably the causes, prevention and treatment of premature death and disability in developed and developing countries.
  • ·          Large-scale research often involves the collection and storage of tens of thousands of human samples from around the World and samples may be stored for decades prior to use.  This can create a unique set of challenges to provide suitable sample collection, processing, transport and storage. 
  • ·          Assay requirements may differ between projects; from simple biomarker investigations up to ‘Omic’ studies and involve a few thousand samples up to several hundred thousand. Biobanking solutions need to be flexible to meet changing demands in biomarker analysis.
  • ·          Sample stability studies are paramount to support the utility of large-scale biobanks. The experience of CTSU and UK Biobank.
  • 14:20 Panel discussion: strategies for sample usage

    Anne Bahr

    Anne Bahr, Data Protection Officer, Sanofi-Aventis

    Amir Gander

    Amir Gander, Senior Knowledge Transfer Associate, UCL Medical School Royal Free Campus

    Paul Whittaker

    Paul Whittaker, Unit Head for Pre-Clinical Biomarkers, Novartis Horsham Research Centre

    15:00 Chairman's closing remarks

    15:10 Afternoon tea

    +

    Biobanking 2013 Attendee List

    Download

    Holiday Inn Regents Park

    Carburton Street
    London W1W 5EE
    United Kingdom

    Holiday Inn Regents Park

    Choose the well-connected Holiday Inn London-Regent's Park hotel, with a superb central London location and speedy transport links. Holiday Inn London-Regent's Park is in a leafy and cosmopolitan area of central London, a 10-minute walk from bustling Oxford Street. Leave your car in our NCP managed underground car park, and explore London by Tube. Great Portland Street Tube station is 25 metres from the hotel, from where you can reach the City and Canary Wharf in 30 minutes, and London Heathrow Airport in 45 minutes.

    Wireless Internet is available throughout the hotel, and you can invite up to 300 people to events at the Academy Conference Centre, with an IT technician and break-out zones. Holiday Inn London-Regent's Park is a 10-minute walk from Santander's offices and businesses in the BT Tower. Stroll 5 minutes to Regent's Park, where you'll find London Zoo and pretty Primrose Hill. We're a 10-minute walk from Bond Street boutiques and 20 minutes from Buckingham Palace and cruises on the River Thames.

    Ask our Concierge to plan your day out and book West End theatre tickets. Room Service is available 24 hours at Holiday Inn London-Regent's Park, or dine in the vibrant Junction Restaurant. Our Junction Bar has a menu of light bites, and a hot breakfast buffet is served daily.

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.